Actimmune® is indicated for chronic granulomatous disease (CGD) and severe, malignant osteopetrosis

Our development programs are focused in the areas of pulmonology and hepatology.

View Development Pipeline

	February 1, 2010 InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 January 20, 2010 InterMune Announces Pricing of $98.7 Million Public Offering of Common Stock
	View All Press Releases

	January 13, 2010 Replay of Webcast - InterMune Inc. at JPMorgan Healthcare Conference
	View Our Event Calendar